Abstract
<h2>ABSTRACT</h2> The role of second-line treatments after first-line chemotherapy in metastatic gastric cancer is reinforcing. Two different options, chemotherapy and anti-VEGFR therapy, are available and confirmed efficacy in this setting. The combination of the two strategies as used in other cancers is promising and could become a new standard for second-line treatment of metastatic gastric cancer. The results of the RAINBOW trial, a phase III study evaluating ramucirumab in combination with paclitaxel versus paclitaxel alone, will add new information on this topic considering that the study met its primary end point of improved overall survival.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
